A case report of severe drug-induced immune hemolytic anemia caused by piperacillin

Front Immunol. 2024 Nov 6:15:1478545. doi: 10.3389/fimmu.2024.1478545. eCollection 2024.

Abstract

Piperacillin is a beta-lactamase inhibitor frequently used in the treatment of urinary tract infections. It is a broad-spectrum antibiotic with strong antibacterial action against Pseudomonas aeruginosa and Enterobacter, especially extended-spectrum beta-lactamase-producing Enterobacteria and Enterococcus. Side effects of piperacillin include allergic reactions, rashes such as urticaria, leukopenia, interstitial nephritis, asthma attacks, serological reactions, candida infection, and bleeding with more severe reactions resulting in anaphylactic shock. Anemia and hemolytic anemia are rare adverse reactions to piperacillin, with an incidence of 0.01-0.10%. We report herein the case of a severe postoperative immune hemolytic reaction to piperacillin. Fortunately, we quickly recognized and identified the drug reaction caused by piperacillin, immediately stopped the use of piperacillin, and performed a blood transfusion. The patient recovered and was subsequently discharged from the hospital.

Keywords: autoimmune hemolytic anemia; drug-induced immune hemolytic anemia; human leukocyte antigen; piperacillin; transfusion.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Hemolytic* / chemically induced
  • Anemia, Hemolytic* / diagnosis
  • Anemia, Hemolytic* / immunology
  • Anti-Bacterial Agents* / adverse effects
  • Humans
  • Piperacillin* / adverse effects

Substances

  • Anti-Bacterial Agents
  • Piperacillin

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This paper was supported by Sichuan Medical Association: S22005 and National Natural Science Foundation of China:82401959.